MEDS.US DataMEDS AI, Inc.
- Market cap
- USD 3.86M
- P/E
- -
- P/B
- 80.90x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is MEDS.US undervalued?
Graham numberThe Graham number of DataMEDS AI, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
DataMEDS AI, Inc. fundamental analysis
No fundamental analysis for DataMEDS AI, Inc. yet.
DataMEDS AI, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About DataMEDS AI, Inc.
DataMEDS AI, Inc. operates as a health IT company in the United States. The company focuses on the vertical integration of technology, pharmacy, pharmaceutical-adjacent, and telemedicine business units to deliver an enhanced healthcare experience for consumers. It offers tools, such as the EinsteinRx, a pharmacy dispensing AI platform; the PharmacyChain, a smart contracts platform; Patient Rx Adherence Tool; and HubRx AI. It also operates as a pharmacy distributor; and provi…
Full company profileDataMEDS AI, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
DataMEDS AI, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 32.8M | 0.00 | 18.1M | 23.3M | 8.01M |
| Gross Profit | 5.75M | 0.00 | 1.77M | -9.64M | 570K |
| Operating Income | -3.42M | -2.88M | -6.15M | -81.2M | -22.3M |
| EBITDA | -369K | -2.88M | -4.91M | -93.5M | -4.88M |
| Net Income | -2.74M | -2.90M | -6.86M | -101M | -20.7M |
| EPS | -2.90 | -3.24 | -6.60 | -71 | -5.22 |
| Balance Sheet | |||||
| Total Assets | 0.00 | 338K | 57.3M | 30.5M | 38.7M |
| Total Liabilities | 5.25K | 3.24M | 50.6M | 42.9M | 38.6M |
| Shareholders' Equity | -5.25K | -2.90M | 6.73M | -12.4M | -1.70M |
| Cash & Short-term Investments | 0.00 | 1.36K | 1.03M | 42.6K | 477K |
| Total Debt | - | 700K | 25.1M | 24.8M | 19.8M |
| Cash Flow | |||||
| Operating Cash Flow | 0.00 | -349K | -1.22M | -10.9M | -12.3M |
| Capital Expenditure | 0.00 | 0.00 | 377K | 882K | 1.19M |
| Free Cash Flow | 0.00 | -349K | -1.60M | -11.7M | -12.3M |
| Ratios | |||||
| ROE | - | - | -101.8% | - | - |
| ROA | - | -855.8% | -12.0% | -332.5% | -53.4% |
| Net Profit Margin | -8.4% | - | -37.8% | -433.9% | -258.2% |
| Debt to Equity | - | - | 3.73x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
DataMEDS AI, Inc. dividends
DataMEDS AI, Inc. has not paid dividends in the last 4 fiscal years.
Last stock split: 1:50 on May 26, 2026.
Who owns DataMEDS AI, Inc.
- Insiders 44.20%
- Institutions 1.78%
- Public & others 54.03%
- Shares outstanding 5.18M
- Free float 1.46M
Top funds holding MEDS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 11.7K | 0.23% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 1.51K | 0.03% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 947.00 | 0.02% | 0.00% | Sep 2026 |
Top institutions holding MEDS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Jane Street Group LLC | 20.5K | 0.72% | +992.13% | Jun 2026 |
| Geode Capital Management, LLC | 12.5K | 0.44% | -12.30% | Jun 2026 |
| Vanguard Capital Management, LLC | 11.1K | 0.39% | -8.27% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 6.19K | 0.22% | -0.02% | Jun 2026 |
| Barclays PLC | 723.00 | 0.03% | 0.00% | Jun 2026 |
| Tower Research Capital LLC | 678.00 | 0.02% | 0.00% | Jun 2026 |
| Fortitude Family Office LLC | 118.00 | 0.00% | 0.00% | Jun 2026 |
| Integrated Wealth Concepts LLC | 25.00 | 0.00% | 0.00% | Jun 2026 |
| Mercer Global Advisors Inc. | 20.00 | 0.00% | 0.00% | Jun 2026 |
| Global Retirement Partners, LLC. | 2.00 | 0.00% | 0.00% | Jun 2026 |
| Danske Bank A/S. | 1.00 | 0.00% | 0.00% | Jun 2026 |
| State Street Corp | 0.00 | 0.00% | -100.00% | Jun 2026 |
| VALLEY FORGE INVESTMENT CONSULTANTS INC ADV | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Sentinus, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Northern Trust Corp | 0.00 | 0.00% | -100.00% | Jun 2026 |
| AQR Capital Management LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| ACT Advisors, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| XTX Topco Ltd | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Point72 Asset Management, L.P. | 0.00 | 0.00% | -100.00% | Jun 2026 |
DataMEDS AI, Inc. company profile
- Company name
- DataMEDS AI, Inc.
- Ticker
- MEDS.US
- Exchange
- USA Stocks
- Listed since
- Feb 21, 2025
- Sector
- Healthcare
- Industry
- Medical Distribution
- Fiscal year end
- December
- Address
- 3000 Bayport Drive, Tampa, FL, United States, 33607
- Phone
- 844 203 6092
- Website
- datamedsai.com
About DataMEDS AI, Inc.
DataMEDS AI, Inc. operates as a health IT company in the United States. The company focuses on the vertical integration of technology, pharmacy, pharmaceutical-adjacent, and telemedicine business units to deliver an enhanced healthcare experience for consumers. It offers tools, such as the EinsteinRx, a pharmacy dispensing AI platform; the PharmacyChain, a smart contracts platform; Patient Rx Adherence Tool; and HubRx AI. It also operates as a pharmacy distributor; and provides clinical concierge services. DataMEDS AI, Inc., through its subsidiary develops and delivers a portfolio of products to guide physicians and patients with difficult clinical decisions throughout the cancer care continuum. In addition, the company develops and provides functional precision medicine oncology platform. The company was formerly known as Wellgistics Health, Inc. and changed its name to DataMEDS AI, Inc. in July 2026. DataMEDS AI, Inc. was incorporated in 2022 and is based in Tampa, Florida.
DataMEDS AI, Inc. management
7- Mr. Prashant Patel M.Sc., R.Ph.Interim Co-CEO, President & Director · born 1974
- Mr. Eric Michael Sherb CPAInterim-CFO · born 1987
- Mr. Gerald E. CommissiongInterim Co-Chief Executive Officer · born 1982
- Mr. Brett ThompsonChief Technology Officer
- Dr. Shafaat Pirani Pharm.D.Chief Clinical Officer · born 1989
- Mr. Nikul Panchal BCNP, R.Ph.Senior Vice President of Pharmacy · born 1977
- Raj Mehta M.B.A., R.Ph.SVP of Tech and Hub